|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
increases transport |
EXP ISO |
ABCB11 protein results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression multiple interactions |
ISO |
notoginsenoside R1 results in increased expression of ABCB1 mRNA NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of ABCB1 mRNA] notoginsenoside R1 results in increased expression of ABCB1A mRNA |
CTD |
PMID:25472953 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases transport |
ISO |
ABCC1 protein results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases transport |
EXP ISO |
ABCC2 protein results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases transport |
EXP ISO |
ABCG2 protein results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO |
notoginsenoside R1 results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of AKT1 protein]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:33689844 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased abundance of Glutathione]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased expression of MIR20A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Triglycerides]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IFNG protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL2 protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR126A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR21A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of TNF protein] |
CTD |
PMID:24933211 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO EXP |
notoginsenoside R1 inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of APP protein modified form] notoginsenoside R1 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK8 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:24975829 PMID:25714973 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Atp5f1d |
ATP synthase F1 subunit delta |
multiple interactions |
EXP |
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein] |
CTD |
PMID:25305180 |
|
NCBI chr 7:9,560,604...9,565,919
Ensembl chr 7:9,560,608...9,565,929
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; Cyclosporine inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; notoginsenoside R1 inhibits the reaction [Excitatory Amino Acid Agonists results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein] notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [Acrylamide results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased expression of BAX protein] |
CTD |
PMID:19224577 PMID:24975829 PMID:25305180 PMID:31971015 PMID:33689844 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein] 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [Acrylamide results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein] notoginsenoside R1 results in increased expression of BCL2 |
CTD |
PMID:19224577 PMID:20023602 PMID:23170834 PMID:24975829 PMID:25305180 PMID:31971015 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of BGLAP mRNA] |
CTD |
PMID:26362186 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of BID protein modified form] |
CTD |
PMID:23170834 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]]; 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]]; Cyclosporine inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]]; MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP3 protein]]; notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CASP3 protein modified form]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein] 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Acrylamide results in increased expression of CASP3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein] |
CTD |
PMID:23170834 PMID:24437944 PMID:24720662 PMID:24975829 PMID:25305180 PMID:25738436 PMID:31971015 PMID:33689844 PMID:38316350 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP8 protein] |
CTD |
PMID:23170834 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO EXP |
MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP9 protein]]; notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP9 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP9 protein] notoginsenoside R1 inhibits the reaction [Acrylamide results in increased expression of CASP9 protein] |
CTD |
PMID:23170834 PMID:31971015 PMID:38316350 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased activity of CAT protein] |
CTD |
PMID:25503068 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein] |
CTD |
PMID:23170834 PMID:25472953 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Chat |
choline O-acetyltransferase |
increases expression |
ISO |
notoginsenoside R1 results in increased expression of CHAT |
CTD |
PMID:25714973 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of CHUK protein modified form] |
CTD |
PMID:25472953 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
EXP |
notoginsenoside R1 results in decreased activity of CYP1A2 protein |
CTD |
PMID:25834921 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression |
ISO |
notoginsenoside R1 results in increased expression of CYP3A4 mRNA |
CTD |
PMID:25472953 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases expression |
ISO EXP |
notoginsenoside R1 results in increased phosphorylation of and results in increased activity of ESR1 protein [1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole results in decreased activity of ESR1 protein] which results in decreased susceptibility to notoginsenoside R1; [notoginsenoside R1 co-treated with Lipopolysaccharides] results in increased expression of ESR1 protein; fulvestrant inhibits the reaction [[notoginsenoside R1 co-treated with Lipopolysaccharides] results in increased expression of ESR1 protein] notoginsenoside R1 results in increased expression of ESR1 protein notoginsenoside R1 results in increased expression of ESR1; notoginsenoside R1 results in increased expression of ESR1 mRNA; notoginsenoside R1 results in increased expression of ESR1 protein |
CTD |
PMID:23170834 PMID:24720662 PMID:25738436 PMID:26362186 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
increases expression |
EXP |
notoginsenoside R1 results in increased expression of ESR2 |
CTD |
PMID:24720662 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of F3 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of F3 protein] |
CTD |
PMID:9102164 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of FAS mRNA] |
CTD |
PMID:23170834 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased expression of FN1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of FN1 mRNA] |
CTD |
PMID:16632126 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
EXP |
Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of GCLC protein] |
CTD |
PMID:24437944 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
multiple interactions |
ISO |
[GRIN1 protein co-treated with GRIN2B protein] results in increased susceptibility to notoginsenoside R1 |
CTD |
PMID:19224577 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
ISO |
[GRIN1 protein co-treated with GRIN2B protein] results in increased susceptibility to notoginsenoside R1 |
CTD |
PMID:19224577 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases expression |
ISO EXP |
fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]; wortmannin inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]] notoginsenoside R1 results in increased expression of GSK3B protein modified form |
CTD |
PMID:23170834 PMID:24720662 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of HMOX1 protein] notoginsenoside R1 results in increased expression of HMOX1; notoginsenoside R1 results in increased expression of HMOX1 protein |
CTD |
PMID:24437944 PMID:24720662 PMID:25422538 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] |
CTD |
PMID:23170834 PMID:25472953 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ide |
insulin degrading enzyme |
multiple interactions increases expression |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [notoginsenoside R1 results in increased expression of IDE] |
CTD |
PMID:25714973 |
|
NCBI chr 1:235,002,984...235,102,448
Ensembl chr 1:234,995,351...235,102,440
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IFNG protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG protein] |
CTD |
PMID:23170834 PMID:24933211 PMID:25472953 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IKBKB protein modified form] |
CTD |
PMID:25472953 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
notoginsenoside R1 promotes the reaction [Lipopolysaccharides results in increased expression of IL10 protein] |
CTD |
PMID:23170834 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il15 |
interleukin 15 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL15 mRNA] |
CTD |
PMID:25472953 |
|
NCBI chr19:25,640,025...25,706,818
Ensembl chr19:25,640,251...25,706,820
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1A mRNA] |
CTD |
PMID:25472953 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; Fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:23170834 PMID:25472953 PMID:25738436 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL2 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL2 mRNA] |
CTD |
PMID:24933211 PMID:25472953 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL6 protein] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; Fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:17655881 PMID:23170834 PMID:24933211 PMID:25472953 PMID:25738436 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ilk |
integrin-linked kinase |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Streptozocin results in increased activity of ILK protein] |
CTD |
PMID:25503068 |
|
NCBI chr 1:160,088,839...160,095,140
Ensembl chr 1:160,088,897...160,095,140
|
|
G |
Itga3 |
integrin subunit alpha 3 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 mRNA]; notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 protein]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGA3 mRNA]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGA3 protein] |
CTD |
PMID:25503068 |
|
NCBI chr10:79,990,160...80,022,206
Ensembl chr10:79,990,161...80,022,118
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAM protein] |
CTD |
PMID:17655881 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGB1 mRNA]; notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGB1 protein]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGB1 mRNA]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGB1 protein] |
CTD |
PMID:25503068 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itgb2 |
integrin subunit beta 2 |
decreases expression multiple interactions |
ISO EXP |
notoginsenoside R1 results in decreased expression of ITGB2 protein notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGB2 protein] |
CTD |
PMID:17655881 PMID:18176958 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Jak1 |
Janus kinase 1 |
increases phosphorylation |
ISO |
[notoginsenoside R1 results in increased phosphorylation of JAK1 protein] which results in increased phosphorylation of STAT3 protein; notoginsenoside R1 results in increased phosphorylation of JAK1 protein |
CTD |
PMID:38316350 |
|
NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased secretion of LDHA protein] |
CTD |
PMID:38316350 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein] notoginsenoside R1 results in increased phosphorylation of MAPK1 protein fulvestrant inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK1 mRNA]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16458614 PMID:16632126 PMID:24437944 PMID:24975829 PMID:25004876 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP ISO |
fulvestrant inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK3 mRNA]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK3 protein] notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16458614 PMID:16632126 PMID:24437944 PMID:24975829 PMID:25004876 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:24975829 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:24975829 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
increases expression multiple interactions increases activity |
ISO |
notoginsenoside R1 results in increased expression of MCL1 mRNA; notoginsenoside R1 results in increased expression of MCL1 protein [notoginsenoside R1 results in increased phosphorylation of STAT3 protein] which results in increased expression of MCL1 mRNA; cryptotanshinone inhibits the reaction [notoginsenoside R1 results in increased expression of MCL1 protein]; MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP3 protein]]; MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP9 protein]] notoginsenoside R1 results in increased activity of MCL1 promoter |
CTD |
PMID:38316350 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mir126a |
microRNA 126a |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR126A mRNA] |
CTD |
PMID:24933211 |
|
NCBI chr 3:9,415,063...9,415,180
Ensembl chr 3:9,415,063...9,415,180
|
|
G |
Mir20a |
microRNA 20a |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased expression of MIR20A mRNA] |
CTD |
PMID:24933211 |
|
NCBI chr15:92,181,084...92,181,168
Ensembl chr15:92,181,084...92,181,168
|
|
G |
Mir21 |
microRNA 21 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR21A mRNA] |
CTD |
PMID:24933211 |
|
NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions decreases expression |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] notoginsenoside R1 results in decreased expression of MPO protein |
CTD |
PMID:20023602 PMID:25472953 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization multiple interactions |
ISO EXP |
notoginsenoside R1 affects the localization of NFE2L2 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased expression of and affects the localization of NFE2L2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 results in increased expression of and affects the localization of NFE2L2 protein]; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased expression of and affects the localization of NFE2L2 protein]; notoginsenoside R1 results in increased expression of and affects the localization of NFE2L2 protein NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide affects the localization of NFE2L2 protein] |
CTD |
PMID:24437944 PMID:24720662 PMID:25422538 PMID:33689844 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; notoginsenoside R1 promotes the reaction [Lipopolysaccharides results in increased expression of NFKBIA mRNA] fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]; wortmannin inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]] |
CTD |
PMID:9102164 PMID:23170834 PMID:25472953 PMID:25738436 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] [notoginsenoside R1 results in increased phosphorylation of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; notoginsenoside R1 results in increased phosphorylation of and results in increased activity of NOS2 protein |
CTD |
PMID:23170834 PMID:25472953 PMID:26045775 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NOS3 protein] |
CTD |
PMID:23170834 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
EXP |
Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of NQO1 protein] |
CTD |
PMID:24437944 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases response to substance increases activity |
ISO |
notoginsenoside R1 binds to and results in increased activity of NR1I2 protein; NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of UGT1A1 mRNA] NR1I2 protein results in increased susceptibility to notoginsenoside R1 notoginsenoside R1 results in increased activity of NR1I2 protein |
CTD |
PMID:25472953 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of PARP1 protein modified form] |
CTD |
PMID:23170834 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Plat |
plasminogen activator, tissue type |
increases expression multiple interactions |
ISO |
notoginsenoside R1 results in increased expression of PLAT mRNA; notoginsenoside R1 results in increased expression of PLAT protein notoginsenoside R1 results in increased expression of [PLAT protein binds to SERPINE1 protein] |
CTD |
PMID:8018658 PMID:9220151 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plau |
plasminogen activator, urokinase |
increases expression |
ISO |
notoginsenoside R1 results in increased expression of PLAU mRNA; notoginsenoside R1 results in increased expression of PLAU protein |
CTD |
PMID:9220151 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [notoginsenoside R1 results in increased expression of PPARG] |
CTD |
PMID:25714973 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
multiple interactions |
EXP |
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased phosphorylation of PPP1R12A protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:25305180 |
|
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of APP protein modified form] |
CTD |
PMID:25714973 |
|
NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:25472953 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of RELA protein modified form]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein modified form] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and affects the localization of RELA protein]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and affects the localization of RELA protein] |
CTD |
PMID:23170834 PMID:25472953 PMID:25738436 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of ROCK1 protein] |
CTD |
PMID:25305180 |
|
NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression multiple interactions |
ISO |
notoginsenoside R1 results in increased expression of RUNX2 mRNA fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of RUNX2 mRNA] |
CTD |
PMID:26362186 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sele |
selectin E |
decreases expression |
ISO |
notoginsenoside R1 results in decreased expression of SELE protein |
CTD |
PMID:18176958 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions decreases activity |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of SERPINE1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of SERPINE1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of SERPINE1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of SERPINE1 mRNA]; notoginsenoside R1 results in increased expression of [PLAT protein binds to SERPINE1 protein] notoginsenoside R1 results in decreased activity of SERPINE1 protein |
CTD |
PMID:8018658 PMID:9102164 PMID:16458614 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
EXP ISO |
SLCO1B2 protein binds to and results in increased transport of notoginsenoside R1 SLCO1B3 protein binds to and results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Sp7 |
Sp7 transcription factor |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of SP7 mRNA] |
CTD |
PMID:26362186 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of SPARC mRNA] |
CTD |
PMID:26362186 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Sqstm1 |
sequestosome 1 |
affects localization multiple interactions |
ISO |
notoginsenoside R1 affects the localization of SQSTM1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 affects the localization of SQSTM1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate affects the localization of SQSTM1 protein]]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate affects the localization of SQSTM1 protein] |
CTD |
PMID:33689844 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions increases phosphorylation |
ISO |
[notoginsenoside R1 results in increased phosphorylation of STAT3 protein] which results in increased expression of MCL1 mRNA; notoginsenoside R1 results in increased phosphorylation of and results in increased localization of STAT3 protein [notoginsenoside R1 results in increased phosphorylation of JAK1 protein] which results in increased phosphorylation of STAT3 protein |
CTD |
PMID:38316350 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of SERPINE1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of FN1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of SERPINE1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] notoginsenoside R1 results in decreased expression of TNF |
CTD |
PMID:9102164 PMID:16458614 PMID:16632126 PMID:20023602 PMID:23170834 PMID:24933211 PMID:25472953 PMID:25738436 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNFRSF1A mRNA] |
CTD |
PMID:23170834 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TRP53 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TRP53 protein] |
CTD |
PMID:23170834 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression multiple interactions |
EXP |
notoginsenoside R1 results in increased expression of TXN1 protein notoginsenoside R1 inhibits the reaction [Acrylamide results in decreased expression of TXN1 protein] |
CTD |
PMID:31971015 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression multiple interactions |
ISO |
notoginsenoside R1 results in increased expression of UGT1A1 mRNA NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of UGT1A1 mRNA] |
CTD |
PMID:25472953 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein] |
CTD |
PMID:23170834 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|